Senate Passes CR With ‘Clean’ User Fee Reauthorization Attached

One day before the end of the fiscal year, the U.S. Senate passed a continuing resolution (CR) with FDA user fee authorization attached to it, moving closer to an 11th-hour funding of about half of the agency’s budget for the next five-years.
Source: Drug Industry Daily